CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4.1% – What’s Next?

CRISPR Therapeutics AG (NASDAQ:CRSP) was down 4.1% on Thursday . The stock traded as low as $49.22 and last traded at $50.86. Approximately 1,325,701 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 2,376,089 shares. The stock had previously closed at $53.02.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CRSP shares. The Goldman Sachs Group reduced their price objective on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Needham & Company LLC restated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Stifel Nicolaus lowered their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a report on Thursday, February 13th. Royal Bank of Canada lowered their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a report on Wednesday, February 12th. Finally, Citigroup lowered their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a report on Tuesday. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $74.40.

CRISPR Therapeutics Stock Down 5.0 %

The company has a market capitalization of $4.11 billion, a price-to-earnings ratio of -10.96 and a beta of 1.67. The business has a 50-day moving average price of $42.25 and a 200-day moving average price of $46.06.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. As a group, sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $71,000. Sunbelt Securities Inc. grew its stake in shares of CRISPR Therapeutics by 108.6% during the fourth quarter. Sunbelt Securities Inc. now owns 6,165 shares of the company’s stock worth $238,000 after purchasing an additional 3,210 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of CRISPR Therapeutics by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company’s stock worth $27,166,000 after purchasing an additional 13,865 shares during the period. Woodline Partners LP grew its stake in shares of CRISPR Therapeutics by 1.6% during the fourth quarter. Woodline Partners LP now owns 101,600 shares of the company’s stock worth $3,999,000 after purchasing an additional 1,600 shares during the period. Finally, Westwood Holdings Group Inc. grew its stake in CRISPR Therapeutics by 18.1% in the fourth quarter. Westwood Holdings Group Inc. now owns 53,102 shares of the company’s stock valued at $2,090,000 after acquiring an additional 8,120 shares during the period. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.